Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono, Johann; Oudard, Stephane; Ozguroglu, Mustafa; Hansen, Steinbjorn; Machiels, Jean-Pascal; Kocak, Ivo; Gravis, Gwenaelle; Bodrogi, Istvan; Mackenzie, Mary; Shen, Liji; Roessner, Martin; Gupta, Sunil; Sartor, A.

doi:10.1016/s0140-6736(10)61389-x

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Copy For Citation

de Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., ...More

LANCET, vol.376, no.9747, pp.1147-1154, 2010 (SCI-Expanded)

Publication Type: Article / Article
Volume: 376 Issue: 9747
Publication Date: 2010
Doi Number: 10.1016/s0140-6736(10)61389-x
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1147-1154
Istanbul University Affiliated: Yes

Abstract

Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.